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CASE REPORT
Extraskeletal osteosarcoma of the orbit
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Abstract
Patient. We report a 22-year-old male presenting with extraskeletal osteosarcoma of the orbit.
Discussion. Extra skeletal osteosarcomas are uncommon tumours, usually arising from the lower extremities or girdle.
These are aggressive tumours with high metastatic potential and poor outcome. Optimal treatment is unde® ned, and the
role of radical surgery, radiotherapy and aggressive chemotherapy is currently being evaluated. The orbit is a rare site for
extraskeletal osteosarcoma, with the only previous case reported in an 11-year-old male, who was irradiated in infancy for
a retinoblastoma.
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Case report
A twenty-two-year-old man presented with a 1-year
history of gradually increasing swelling of the left
eye and occasional pain. On the whole, patient was
well nourished and had no evidence of lymphnode
enlargement. There was proptosis of the left eye
with oedema in the upper eyelid. The conjunctiva
showed mild congestion, and the cornea, anterior
chamber and lens were clinically normal. Vision and
ocular movements were normal. There was no evi-
dence of raised intra-cranial pressure, meningeal
irritation or focal neurological de® cits. All other
systems were normal.
Blood count and serum chemistry were normal.
CT scan of the head revealed a well-circumscribed
homogeneous mass in the supero-medial aspect of
the left orbit, with non-homogeneous contrast en-
hancement (Fig. 1). The mass appeared separate
from the globe and the bony orbital wall. On MRI,
the lesion was homogeneously hypo-intense on T1-
and hyper-intense on T2-weighted images. The pa-
tient underwent left frontal transcranial orbitotomy
and complete excision of the orbital tumour. At
surgery the tumour was found not attached to the
orbital walls or extra-ocular muscles. It was sepa-
rated by blunt dissection and entirely removed with-
w
Fig. 1. CT scan of the head showing the intra-orbital tumour.
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Fig. 2. Extraskeletal osteosarcoma of orbit, with predominant
spindle cell sarcomatous areas interspersed with neoplastic osteoid
and focus of calci® cation (H&E; low power views).
usually present in the fourth and ® fth decades of life
in contrast to their osseous counterparts.
1± 4 Some
series report a male predominance, whereas others
show no sex predilection.
3,5
The extremities and girdles, especially lower, are
most commonly involved.
5 There are also reports of
such tumours involving the face, breast, abdominal
wall, soft tissues of the back and retroperi-
toneum.
2,3,5 Fine and Stout reported a case of osteo-
genic sarcoma arising at the site of a vaccination
scar.
5 Kauffman and Stout reported the case of an
11-year-old boy developing orbital extraskeletal os-
teosarcoma, following radiation therapy for
retinoblastoma in infancy.
6 The role of trauma in
the development of extraskeletal osteosarcomas is
controversial, though a history of trauma can be
elicited in 13% of patients with these tumours.
3 The
insidious evolution of osteogenic sarcoma in myosi-
tis ossis® cans was described by Shanoff et al.
7 and
around 16% of extraskeletal osteosarcomas have
developed in myositis ossi® cans.
5
Radiotherapy is known to predispose to the devel-
opment of both soft tissue and bone sarcomas. In a
series by Sordillo et al.,
2 10% of the patients had
previous irradiation to the area where extraskeletal
osteogenic sarcomas developed, with a median in-
terval of 15 years for development of these tumours.
Our patient gave no history of trauma or previous
radiotherapy to the eye.
Fig. 3. Extraskeletal osteosarcoma of the orbit, showing
neoplastic osteoid (H&E; high power view).
out excision of bone or muscle. Post-operative
evaluation showed normal function of all ocular
muscles.
On macroscopic examination the tumour was
3 3 3.5 cm in size, well circumscribed and ® rm in
consistency. It showed greyish white areas on cut
sections. Microscopy showed predominantly spindle
cell sarcomatous areas interspersed with abundant
neoplastic osteoid. Focal areas of neoplastic carti-
lage and osteoid with calci® cation were also evident
(Figs 2± 4).
Post-operative scanning showed no evidence of
residual disease in the orbit, and CT scans of the
chest and abdomen and radionucleide bone scan
showed no evidence of disease elsewhere. The pa-
tient was unwilling to undergo orbital exenteration
or local radiotherapy. He received six cycles of
combination chemotherapy with cisplatin, ifos-
famide and doxorubicin and is alive and free of
disease 2 years after diagnosis.
Discussion
Extraskeletal osteogenic sarcoma is unusual and
reportedly accounts for only 2± 4% of osteosar-
comas.
1± 4 Patients with extraskeletal osteosarcomasExtraskeletal osteosarcoma of orbit 123
Fig. 4. Extraskeletal osteosarcoma of the orbit, showing spindle
cell area (H&E; high power view).
volvement being lung, regional lymph nodes and
bone.
5,10± 12
Treatment of these tumours has traditionally been
radical surgery with or without additional radiation.
Various chemotherapy protocols have been used in
advanced and metastatic disease and the outcome
was uniformly poor. In the series by Sordillo et al.,
2
four of the ® ve patients who received adjuvant
chemotherapy after surgical excision of recurrent or
metastatic disease were long-term survivors, sug-
gesting that chemotherapy may be of value in an
adjuvant setting.
With the increasing use of chemotherapy, organ
preservation could become feasible in patients with
extraskeletal osteosarcoma. The use of pre-operative
intra-arterial adriamycin infusion and gel embolisa-
tion followed by wide excision of the tumour was
reported by Dhillon et al. for achieving limb preser-
vation.
12 Our experience also suggests that preser-
vation of organ/function could be achieved with
limited surgery and chemotherapy. Chemotherapy
schedules like CyADIC (cyclophosphamide, dox-
orubicin, and dacarbazine) or MAID (Mesna, ifos-
famide, doxorubicin and dacarbazine) are currently
being tried to evaluate response of these tumours
prior to surgery.
13 Though de® nitive guidelines can-
not be made, current data suggest that the optimal
management of these aggressive tumours involves
the use of chemotherapy and organ-preserving
surgery with or without additional radiotherapy.
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